Syros将从纳斯达克退市，从SEC注销

2025-03-01 05:23

Syros Pharmaceuticals (NASDAQ:SYRS) will proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market and the deregistration of its common stock in order to terminate and suspend the company’s reporting obligations, the company said on Friday.
Syros intends to file a Form 25 with the Securities and Exchange Commission to effect the delisting and deregistration of its common stock on or about March 10, 2025 and the delisting is expected to become effective on or about March 20, 2025.
The company expects that the deregistration of its common stock will become effective 90 days after the filing of the Form 15 with the SEC.
On January 6, 2025 the company had received deficiency letters from Nasdaq providing notice that it was out of compliance with the listing rules with the bid price for its common stock closing below $1.00 per share for more than 35 consecutive business days, the minimum value of listed securities of the company’s common stock was below the minimum $50M requirement for more than 30 consecutive business days and the market value of publicly held shares was below the minimum $15M requirement for more than 35 consecutive business days.
Source: Press Release

More on Syros Pharmaceuticals